Stem cell legality is the first question a physician asks before adding a cell or tissue service. It is also the wrong first question. The answer depends on the product’s FDA pathway first, then on the state and its medical board. This guide gives practice owners five rules that settle the question in the right order, before a vendor or a price does.
TLDR: Stem cell legality in the US comes down to the product’s FDA pathway first, then state law. A product that meets all four criteria in 21 CFR 1271.10 can be offered without a biologics license. A product that misses one is regulated as a drug or a biologic. “Registered” is not “approved,” and the FDA has approved only a small number of cell-based products, each for a specific labeled use. Florida adds its own statute on top. Read on for the five rules and the order to ask the questions in.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm or compliance consultancy. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.
When a physician calls me about adding cells or tissue to the practice, the questions arrive in a fixed order. Is it legal in my state? Where can I get it? How much can I charge? The first question feels like a gate. The other two feel like the business.
The trouble is that “legal” is not a yes or a no. The real answer is longer: lawful to offer under the product’s FDA pathway, plus state law. That answer has five parts. They are below, for the owner making the call, not for patients.
Why Stem Cell Legality Starts With the Product
Whether a cell or tissue product may be offered lawfully depends on how the FDA classifies it. Some products are human cells, tissues, and cellular and tissue-based products, called HCT/Ps. Those fall solely under section 361 of the Public Health Service Act. Others are drugs or biologics that need a license first. The words “stem cell” on the box do not tell you which one you hold.
That is why stem cell legality is a product question before it is a state question. A state can add rules, and Florida does. A state cannot move a product from one federal pathway to the other. The FDA decides that, using the four criteria in Part 1271.
The vendor is not the source of the answer either. The rep’s answer to “is it legal” is usually a sales answer. So the first job is to find the pathway.
The Five Rules of Stem Cell Legality
The five rules below settle the question in order: pathway, criteria, registration, state, marketing. Skip one and the others fall over.
Rule 1: Pathway Decides What a Practice May Offer and Say
The product’s pathway decides what a practice may offer and what it may say. If the product meets all four criteria in 21 CFR 1271.10, it falls solely under section 361 and Part 1271. If it misses even one, the full drug and biologics rules apply. That includes premarket review.
Ask the supplier which pathway the product sits on. The 361 versus 351 line is the first thing a marketer has to learn. Once the pathway is named, the four criteria tell you why.
Rule 2: All Four Criteria in 21 CFR 1271.10 Must Be Met
An HCT/P is regulated solely under section 361 only if it meets all four criteria in 21 CFR 1271.10. Here is each one, quoted, then in plain words.
Criterion one says the HCT/P “is minimally manipulated” and no more. In plain words, the processing did not change what the cells or the tissue do. The FDA’s July 2020 guidance on minimal manipulation and homologous use explains how the agency reads this one and the next.
Criterion two says the HCT/P “is intended for homologous use only” and adds a test. That intent is read “as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent” behind it. In plain words, the product does the same basic job in the new body that it did in the donor.
Criterion three covers what may be mixed in. The making of it “does not involve the combination of the cells or tissues with another article” of any kind. The only exceptions are “water, crystalloids, or a sterilizing, preserving, or storage agent” in the rule’s words. Even those pass only if the addition “does not raise new clinical safety concerns with respect to the HCT/P” being made.
Criterion four has two halves. The first half has two parts. The HCT/P “does not have a systemic effect” in the body. And it “is not dependent upon the metabolic activity of living cells for its primary function” either. The second half applies when the product does have a systemic effect or does depend on living cells. Then it passes in three cases only. It “is for autologous use” by the same person. It “is for allogeneic use in a first-degree or second-degree blood relative” of the donor. Or it “is for reproductive use” by the patient.
In plain words, take a living-cell product from an unrelated donor. If it depends on those cells’ metabolic activity, it does not meet criterion four. All four, not three of four. Registration is not part of the test.
Rule 3: Registered Is Not Approved
“FDA registered” is a filing, not a finding. Under 1271.10(b), an establishment that makes a 361 HCT/P “must register with FDA” and list each product. Registration means the agency knows the establishment exists. It is not a review of safety or effectiveness. It is not an approval.
“FDA registered clinic” is the credential claim we see most often on regen sites. In most cases the registration belongs to the establishment that recovers, processes, or stores the product. It does not belong to the clinic that injects it.
The FDA’s consumer alert on regenerative medicine products adds the context. The alert is dated April 2024. It warns that many of these products are marketed illegally and have not been shown to be safe or effective. The same page states that there are currently no FDA approved exosome products. The FDA has approved a small number of cell-based products, and each approval covers a specific labeled indication only.
The approval question playbook covers how to answer it in every channel. With the federal floor set, the state adds the next layer.
Rule 4: State Law and the Medical Board Add a Second Layer
The federal pathway is the floor, not the ceiling. The state adds its own layer through statute and through the medical board. Each state does it differently.
Florida is the worked example. Section 458.3245 of the 2025 Florida Statutes lets a physician licensed under that chapter perform stem cell therapy the FDA has not approved. It must be within the physician’s scope of practice. It must relate to orthopedics, wound care, or pain management.
The cells must be retrieved, manufactured, and stored in a facility that is registered and regulated by the FDA. That same facility must also be certified or accredited by one of four named bodies. Each product lot must come with a post-thaw viability report before use. The physician must also get a signed consent form. It must state that the therapy has not been approved by the FDA.
The ad rule is the part most practices miss. It applies to a physician who performs stem cell therapy under that section. The section also lists exemptions, and counsel decides whether one applies.
For a physician it covers, every ad must carry a notice. It includes the sentence “This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration” word for word. The notice must be clearly legible, in a type size no smaller than the largest type in the ad.
We covered the marketing side in Florida’s stem cell statute and the wider picture in state marketing laws. Counsel reads the practice’s own statute and board rules first. Then the last rule covers the marketing.
Rule 5: Marketing Language Can Turn a Product Into a Drug Claim
The words on the website can change the pathway. Criterion two reads homologous use from the labeling, the ads, and the other signs of the maker’s intent. A claim that the product treats a disease the tissue was never recovered to address can be read as a drug claim.
So a lawful product can be marketed into an unlawful position. “Minimally manipulated” on a service page is not a shield, and we explained why in minimally manipulated is not a strategy. Here is how to work through all five rules.
How to Work Through the Decision in Order
Ask the questions in this order: pathway, criteria, paperwork, state, marketing, then sourcing and price. That order is the whole method. Here is each step.
Step one is the pathway, in writing, from the supplier. Ask which criteria in 1271.10 the product meets and how the supplier knows. A rep who cannot answer is telling you something useful.
Step two is the four criteria, read against how the product is made and what it is meant to do. If any answer is “it depends,” that is a question for counsel. Write the answers down.
Step three is the paperwork: registration and listing, certificate of analysis, and chain of custody for each lot. No paperwork, no step four.
Step four is the state. Put the statute and the board’s ad rules next to the product. A Florida practice settles the source rules, the consent form, and the ad notice before the first page goes live.
Step five is the marketing, written last and written to the pathway. Nothing on the page says more than the paperwork supports.
Step six is sourcing and price, and this is where the talk gets easier. Once the pathway is settled, a first call moves to where owners’ questions nearly always live anyway. Those are customer flow, growth goals, and how the process works. That is where practice consulting starts to earn its place. Here are the mistakes that break the order.
The Stem Cell Legality Mistakes We See Most Often
The most common mistake is treating “FDA registered” as a credential. It is a filing by the establishment. On a homepage, it invites the exact question the practice cannot answer well.
The second mistake is letting the rep write the marketing. Reps routinely say things to clinic owners that are not compliant. That language travels from the pitch into the clinic’s own ads. Sometimes it goes word for word. The rep does not hold the practice’s license.
The third mistake is passing three of the four criteria and calling it done. Criterion four is where donor-derived living-cell products often fall. A brochure rarely mentions it.
The fourth mistake is asking the price question first. A price set before the pathway is a price set on a product the practice does not yet understand. All four show up below.
Picture a Pain Practice That Asked the Questions in the Wrong Order
Picture a pain practice in a mid-sized city. Patients keep asking about “stem cells” because a billboard across town says the words. The owner called with the three questions in the usual order. Is it legal in my state? Where do I get it? What can I charge?
The supplier had already answered all three in one afternoon. Legal, yes, the supplier is FDA registered. Get it from us. Charge what the clinic across town charges. The practice had a brochure, a price, and no idea which pathway the product sat on.
What changed was the order. The practice went back and asked which of the four criteria the product met, and how. Those answers took longer than an afternoon. The state statute and the board’s rules went next to the product. The consent form and the ad notice went to counsel before a service page was written.
The marketing was drafted last, to the pathway, not to the billboard. Sourcing and price came at the end, and they came easier. Nothing about this was faster. It was in order, and order is what keeps stem cell legality defensible if a regulator or a board ever asks.
Frequently Asked Questions
Is Stem Cell Therapy Legal in the US?
There is no flat yes or no on stem cell legality. Whether a cell or tissue product may be offered lawfully depends on its FDA pathway under 21 CFR 1271.10. Then state law and the medical board apply. A 361 HCT/P that meets all four criteria needs no biologics license. Counsel decides the practice’s own case.
What Does “FDA Registered” Actually Mean?
It means an establishment that makes HCT/Ps has filed a registration with the FDA and listed its products, as 1271.10(b) requires. It is a filing, not a review, and not an approval. A clinic that only injects the product usually holds no registration of its own.
Are Any Stem Cell Products FDA Approved Today?
A small number of cell-based products are, each for a specific labeled indication only. The FDA’s consumer alert, dated April 2024, warns that many regenerative medicine products are marketed illegally and have not been shown to be safe or effective. The same page states there are currently no FDA approved exosome products. Counsel confirms any given product’s status.
What Does Florida Require Before a Physician Offers Stem Cell Therapy?
Section 458.3245 lets a Florida physician perform stem cell therapy the FDA has not approved, within scope, for orthopedics, wound care, or pain management. The cells must come from a facility registered with the FDA. That facility must be accredited by one of four named bodies. Each lot needs a post-thaw viability report. The physician needs a signed consent, and each ad must carry the statutory notice. Exemptions exist, so counsel confirms whether the section applies.
Can Marketing Make a Compliant Product Non-Compliant?
Yes. Criterion two of 1271.10 reads homologous use from the labeling, the ads, and the other signs of the maker’s intent. A page that claims the product treats a condition the tissue was not recovered to address can be read as a drug claim. Write the marketing to the pathway, never past it.
Key Takeaways
- Stem cell legality depends first on the FDA pathway, then on state law and the medical board.
- A 361 HCT/P must meet all four criteria in 21 CFR 1271.10, not three of four.
- “FDA registered” is a filing by the establishment, never a review or an approval.
- The FDA has approved only a small number of cell-based products for specific labeled uses, and no exosome product.
- Florida’s section 458.3245 adds scope limits, source rules, a signed consent, and an ad notice.
- Ask pathway, criteria, paperwork, state, and marketing before sourcing and price.
Your Next Step
If the three questions were already asked in the usual order, that is fine. The fix is to ask them again in the right order. We help practices do that work alongside counsel. That means the pathway, the claims on every page, the state layer, and then the service line on top.
Regen Portal does not decide the legal question. We make sure the marketing never says more than the pathway allows.
PS: If you want a second set of eyes on how your pages talk about cells, tissue, and “FDA registered,” send them over for a free compliance audit.
Email: hello@regenportal.com
YouTube: Subscribe to the channel
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has spent nearly 15 years inside regenerative medicine and has helped hundreds of practices, manufacturers, and distributors grow through compliant, high-performance marketing and consulting. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
